重组抗凝蛋白-新蛭素的原核表达研究

doi:10.13523/j.cb.20141210

中国生物工程杂志

2014, Vol. 34

Issue (12): 69-77 DOI: 10.13523/j.cb.20141210

技术与方法

重组抗凝蛋白-新蛭素的原核表达研究

张超¹, 巩蔚¹, 郭莹莹¹, 孙卫国², 姚敏³, 于爱平¹

1. 中国人民解放军军事医学科学院放射与辐射研究所北京 100850;
2. 中国人民解放军第309医院北京 100091;
3. 中国人民解放军医学图书馆北京 100039

The Prokaryotic Expression of an Anti-coagulant Protein of EH

ZHANG Chao¹, GONG Wei¹, GUO Ying-ying¹, SUN Wei-guo², YAO Min³, YU Ai-ping¹

1. Department of Experimental Hematology, Beijing Institute of Radiation Medicine, Beijing 100850, China;
2. The 309 hospital, PLA, Beijing 100091, China;
3. The Medical Library of the Chinese PLA, Beijing 100039, China

全文: PDF(951 KB) HTML

摘要：

目的:重组新蛭素(EH)是在抗凝蛋白水蛭素的氨基末端添加3个氨基酸(EPR)的衍生物,以往EH的表达工艺沿用水蛭素的酵母表达工艺,生产周期长、目标蛋白表达效率相对较低。而水蛭素类的蛋白在大肠杆菌中往往以包涵体形式表达,后期的分离纯化收率较低,无法适应产业化。为了提高EH的生产效率,探索了EH在大肠杆菌中的可溶性表达。方法:首先通过PCR的方法获得eh的cDNA,PCR产物连接入原核表达载体pET-22或pET-24中获得重组表达质粒,将重组表达质粒转化大肠杆菌BL21(DE3)或BL21(plySs),获得重组工程菌BL21(DE3)-pET-24-eh,BL21(DE3)-pET-22-eh,BL21(plySs)-pET-22-eh。重组工程菌进行IPTG诱导,SDS-PAGE和Western blot鉴定表达产物。结果:EH在3个重组工程菌中均可实现可溶性表达。表达水平较高的为BL21(DE3)-pET-24-eh工程菌;之后通过优化诱导温度,时间,诱导剂浓度、诱导前菌种密度,确定最佳条件为:37℃,诱导6h,IPTG浓度为0.4μmol/L,诱导前菌种密度在OD₆₀₀=1左右。诱导产物经分离纯化,其纯度可达96.93%。最后通过蛋白含量测定及抗凝活性检测,确定表达的EH蛋白本身无抗凝活性,被FXa裂解后可以释放出水蛭素的抗凝活性。结论:实现了EH在大肠杆菌中的可溶性表达,表达周期短,有望提高EH的生产效率,为EH的产业化奠定了基础,也为水蛭素类产品的生产提供了新的工艺途径。

关键词： 新蛭素; 原核表达; 可溶性表达; 抗凝

Abstract:

Objective: EH is a derivative of hirudin with three amino acids (EPR) at the amino terminal of hirudin. The expression of EH in yeast has long time of production and low efficiency of expression. To improve the production efficiency of EH, the soluble expression of EH in E. coli was studied. Method: Three recombinant prokaryotic expression engineering bacteria, BL21 (DE3)-pET-24-eh, BL21(DE3)-pET-22-eh, BL21(plySs)-pET-22-eh were constructed. The three engineering bacteria were cultured and EH expression was induced by IPTG. Results: The results of SDS-PAGE and Western blot showed that EH was expressed in intracellular soluble pattern in all three engineering bacteria, and the expression level is better in BL21(DE3)-pET-24-eh. Then in BL21(DE3)-pET-24-eh, the induction temperature, the induction time, the concentration of IPTG and the density of bacteria at induction time were optimized. The optimized condition is as follows: induction at 37 ℃ for 6 h, IPTG concentration is 0.4μmol/L, the bacteria density at induction time is OD₆₀₀ = 1. Finally, the specific anticoagulant activity of purified EH protein (the purity is 96.93%) and the cleavage product of EH by FXa were determined. Conclusion: The results indicated that the intact EH has no anticoagulant activity, and after cleavage with FXa, EH released anticoagulant activity of hirudin. Therefore, the prokaryotic expression system of EH, and EH were constructed which can be expressed in an intracellular soluble pattern. These results will support the subsequent fermentation process and the ultimate industrialization of EH.

Key words: Anticoagulant protein of EH The prokaryotic expression Soluble expression Anticoagulant

收稿日期: 2014-09-09 出版日期: 2014-12-25

ZTFLH:

Q786

基金资助:

国家科技重大专项"重大新药创制"(2012ZX09102301-008)资助项目

通讯作者: 于爱平 E-mail: yuap117@163.com

	服务
	把本文推荐给朋友
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

引用本文:

张超, 巩蔚, 郭莹莹, 孙卫国, 姚敏, 于爱平. 重组抗凝蛋白-新蛭素的原核表达研究[J]. 中国生物工程杂志, 2014, 34(12): 69-77.

ZHANG Chao, GONG Wei, GUO Ying-ying, SUN Wei-guo, YAO Min, YU Ai-ping. The Prokaryotic Expression of an Anti-coagulant Protein of EH. China Biotechnology, 2014, 34(12): 69-77.

链接本文:

https://manu60.magtech.com.cn/biotech/CN/10.13523/j.cb.20141210 或 https://manu60.magtech.com.cn/biotech/CN/Y2014/V34/I12/69

[1] Pineo G F, Hull R D.Hirudin and hirudin analogues as new anticoagulant agents. Curr Opin Hematol, 1995, 2(5): 380-385.

[2] Ruef Johannes, Katus Hugo A. New antithrombotic drugs on the horizon. Expert Opinion on Investigational Drugs, 2003, 12 (5): 781-797.

[3] Markwardt F. The development of hirudin as an antithrombotic drug. Thromb Res, 1994, 74(1): 1-23.

[4] Rewinkel J B, Adang A E.Strategies and progress towards the ideal orally active thrombin inhibitor. Current Pharmaceutical Design, 1999, 5(12): 1043-1075.

[5] Wallace A, Dennis S, Hofsteenge J, et al. Contribution of the N-terminal region of hirudin to its interaction with thrombin. Biochemistry, 1989,28(26):10079-10084.

[6] Wirsching F, Opitz T, Dietrich R, et al. Display of functional thrombin inhibitor hirudin on the surface of phage M13. Gene,1997, 204(1-2):177-184.

[7] Syed S, Schuyler P D, Kulczycky M, et al. Potent antithrombin activity and delayed clearance from the circulation characterize recombinant hirudin genetically fused to albumin. Blood,1997,89(9):3243-3252.

[8] McKenzie C R, Abendschein D R, Eisenberg P R. Sustained inhibition of whole-blood clot procoagulant activity by inhibition of thrombus-associated factor Xa. Arterioscler Thromb Vasc Biol,1996,16(10):1285-1291.

[9] 秦晓永,于爱平,王文文,等.抗凝蛋白EH体外活性检测条件的建立.中国生物工程杂志,2011,31 (5):108-112. Qin X Y,YU A P,Wang W W,et al.The antithrombin activity detection of EH in vitro.China Biotechnology,2011,31(5):108-112.

[10] Zhang Chuanling, Yu Aiping, Yuan Bin, et al. Construction and functional evaluation of hirudin derivatives with low bleeding risk. Thrombosis and Haemostasis, 2008, 99 (2): 324 -330.

[11] 王文文.抗凝蛋白的药效学及蛋白表达的优化.天津:天津大学,2012. Wang W W.Pharmacodynamic study of EH and optimization of its expression.Tianjin:Tientsin University,2012.

[12] 郝木强,李彦英,刘春杰, 等. 重组低出血抗凝蛋白在毕赤酵母中的中试发酵工艺研究及其纯化与鉴定.生物技术通讯,2013,(3):314-319. Hao M Q, Li Y Y, Liu C J,et al. Pilot-scale fermentation study of a low bleeding anticoagulant protein in Pichia pastoris.Letters in Biotechnology,2013,3:314-319.

[13] 国家药典委员会.中华人民共和国药典(三部).北京:中国医药科技出版社,2010.附录34-35. Chinese Pharmacopoeia Commission.Pharmacopoeia of the People's Republic of China(3 Volumes).Beijing:China Medical Science Press,2010:Appendi 34-35.

[14] Poet P, Scacheri E, Benatti L,et al. Production of the HV 1 variant of hirudin by recombinant DNA methodology. Blood Coagul Fibrinolysis, 1991,2(1):113120.

[15] Jizhong Yang, Xiangshan Zhou, Yuanxing Zhang. Improvement of recombinant hirudin production by controlling NH₄⁺concentration in Pichia pastoris fermentation. Biotechnology Letters, 2004,26(12):1013-1017.

[16] 龙铟,刘家云,刘莉, 等.水蛭素在毕赤酵母中的分泌表达.第四军医大学学报,2006,27 (8):673-676. Long Y,Liu J Y, Liu L,et al.Secretory expression of hirudins in Pichia pastoris.Journal of the Fourth Military Medical University,2006,27(8):673-676.

[1]	乔圣泰,王曼琦,徐慧妮. 番茄SlTpx原核表达蛋白的体外功能分析^*[J]. 中国生物工程杂志, 2021, 41(8): 25-32.
[2]	张磊,唐永凯,李红霞,李建林,徐逾鑫,李迎宾,俞菊华. 促进原核表达蛋白可溶性的研究进展 ^*[J]. 中国生物工程杂志, 2021, 41(2/3): 138-149.
[3]	邓通,周海胜,吴坚平,杨立荣. 基于分子伴侣策略提高NADPH依赖型醇脱氢酶的异源可溶性表达 ^*[J]. 中国生物工程杂志, 2020, 40(8): 24-32.
[4]	张潇航,李媛媛,贾敏晅,顾奇. 弹性蛋白样生物材料的制备及性质鉴定 ^*[J]. 中国生物工程杂志, 2020, 40(8): 33-40.
[5]	吕一凡,李更东,薛楠,吕国梁,时邵辉,王春生. **LbCpf1基因的原核表达、纯化与体外切割检测 ^***[J]. 中国生物工程杂志, 2020, 40(8): 41-48.
[6]	李彤彤,宋彩玲,杨凯越,王文静,陈慧宇,刘明. 抗犬细小病毒VP2蛋白单链抗体的制备与中和活性研究 ^*[J]. 中国生物工程杂志, 2020, 40(4): 10-16.
[7]	陈秋利,杨丽超,李辉,温莎,李刚,何敏. 人Nek2蛋白原核表达纯化及其多克隆抗体制备 ^*[J]. 中国生物工程杂志, 2020, 40(3): 31-37.
[8]	杨隆兵,国果,马慧玲,李妍,赵欣宇,苏佩佩,张勇. 家蝇抗菌肽AMPs17蛋白原核表达条件的优化及其抗真菌活性检测 ^*[J]. 中国生物工程杂志, 2019, 39(4): 24-31.
[9]	许敏华,张晶晶,金小宝,李小波,王艳,马艳. 美洲大蠊内生菌几丁质酶基因的克隆、表达及其活性研究 ^*[J]. 中国生物工程杂志, 2019, 39(1): 31-37.
[10]	李明英,王仁军,张帆,迟彦. β2糖蛋白Ⅰ第五结构域及其突变体、短肽片段的原核表达及活性分析 ^*[J]. 中国生物工程杂志, 2018, 38(8): 1-9.
[11]	陈远侨,龙定沛,豆晓雪,祁润,赵爱春. ELP₃₀-tag蛋白纯化能力的原核表达研究[J]. 中国生物工程杂志, 2018, 38(2): 54-60.
[12]	何亚南,孙钰椋,任雅坤,梁盛英,杨芬,刘彦礼,林俊堂. 金黄色葡萄球菌类肠毒素K与GFP融合蛋白工程菌的构建及其表达蛋白生物学活性分析 ^*[J]. 中国生物工程杂志, 2018, 38(12): 14-20.
[13]	任建委,李军,李尚泽. 人源CT55蛋白原核表达及单克隆抗体的制备 ^*[J]. 中国生物工程杂志, 2018, 38(11): 1-8.
[14]	孙文佳, 姚宇峰, 杨旭, 黄惟巍, 刘存宝, 龙琼, 褚晓杰, 马雁冰. 乙肝核心抗原病毒样颗粒呈现HPV 16L1抗原表位及特异抗体诱导[J]. 中国生物工程杂志, 2017, 37(3): 58-64.
[15]	冀君, 朱晨晨, 许鑫, 刘晓, 冷超粮, 史鸿飞, 姚伦广, 阚云超. 鸡贫血病毒凋亡素基因的可溶性融合表达及抗肿瘤活性分析[J]. 中国生物工程杂志, 2017, 37(2): 26-32.

Viewed

Full text

Abstract

Cited

Shared

Discussed